Using CRISPR to Understand and Target the RHBDF2 Gene

Using CRISPR to Understand and Target the RHBDF2 Gene

The RHBDF2 gene, also known as iRhom2, is a fascinating area of research because of its role in a rare genetic disorder called Tylosis (or Howel-Evans syndrome). This condition, characterized by a thickening of the skin on the palms and soles, is strongly linked to a very high lifetime risk of developing esophageal squamous cell carcinoma (ESCC). The link is so strong that Tylosis is considered a single-gene model for inherited esophageal cancer.

The key to understanding this link lies in the function of the RHBDF2 gene. It doesn't cause cancer by itself, but instead, it acts as a regulator for the Epidermal Growth Factor Receptor (EGFR) signaling pathway. In people with Tylosis, specific gain-of-function mutations in the RHBDF2 gene cause it to become overactive. This leads to the enhanced secretion of growth factor ligands, such as amphiregulin (AREG), which then over-stimulate the EGFR pathway. This hyperactive signaling drives uncontrolled cell proliferation, particularly in epithelial cells, leading to both the skin thickening of Tylosis and the predisposition to esophageal cancer.

The Role of CRISPR in RHBDF2 Research

The CRISPR-Cas9 gene editing system has become an essential tool for scientists studying the RHBDF2 gene and its role in disease. CRISPR allows for precise and efficient editing of a cell's DNA, making it perfect for creating disease models and exploring therapeutic strategies. Here's how it's being used:

• Creating Disease Models: Researchers have used CRISPR-Cas9 to create animal models, specifically mice, that carry the exact human gain-of-function mutation in the RHBDF2 gene. These mouse models successfully recapitulate key features of human Tylosis, such as skin hyperproliferation, providing a living system to study the disease mechanism. This allows scientists to investigate the link between the RHBDF2 mutation, EGFR pathway over-activation, and the subsequent development of cancer.

• Investigating Gene Function: Beyond disease modeling, CRISPR is used to perform genetic screens that help researchers understand the intricate functions of RHBDF2. For instance, scientists can use CRISPR to knock out the gene or its regulators to see how it affects cell behavior, such as cell survival, proliferation, and inflammation. This helps to pinpoint which specific pathways are controlled by RHBDF2.

• Exploring Therapeutic Strategies: By creating these precise genetic models, researchers can test potential treatments. For example, some studies have shown that deleting the gene for amphiregulin (a downstream effect of the RHBDF2 mutation) in these mouse models can restore the normal skin phenotype, suggesting that targeting the downstream effects of the mutation could be a viable therapeutic approach for Tylosis. The ability to precisely edit genes with CRISPR opens the door for developing targeted therapies that could one day correct the underlying genetic defect.